Caribou Biosciences, Inc.
NASDAQ:CRBUBiotechnology
-$0.05 today
- Market cap
- $52.47M
- Beta
- 2.33
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$1.39
Volume 1.01M
Average 1.83M
CRBU Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Caribou Biosciences, Inc.NASDAQ: CRBU
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $2.36M fell 39.3% year over year, behind the -32.8% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 13.9% from the prior quarter. Over 3 fiscal years it compounded at +2.7% a year.
Context
- Stock-based compensation amounted to 113.6% of revenue in FY2025, down 53.5 pp from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -39.3% toward the trailing-twelve-month pace of -32.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 12.68M USD
- Year-over-year change
- -24.1%
- 4-year CAGR
- +38.5%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12.68M | -24.1% |
| FY2024 | 2024-12-31 | 16.71M | +21.5% |
| FY2023 | 2023-12-31 | 13.75M | +17.4% |
| FY2022 | 2022-12-31 | 11.72M | +239.7% |
| FY2021 | 2021-12-31 | 3.45M | — |
Stock-Based Compensation vs competitors
How CRBU compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -32.8% is the 7th highest of 11, against a peer median of -10.1%.
- Stock-based compensation amounts to 99.6% of revenue for CRBU, versus a peer median of 59.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $33.74M USD | -35.1% | -23.4% | — | |
| FY2025 | €26.77M EUR | +647.7% | +129.4% | 597.1% | |
| LTM Mar 2026 | $15.77M USD | -32.9% | -11.7% | 22.8% | |
| LTM Mar 2026 | $11.86M USD | +7.9% | +52.0% | 36.3% | |
| LTM Mar 2026 | $11.51M USD | -28.1% | +4.4% | 5116.0% | |
| LTM Mar 2026 | $11.16M USD | -32.8% | +2.7% | 99.6% | |
| LTM Mar 2026 | $10.44M USD | +45.6% | +16.4% | 517.7% | |
| LTM Mar 2026 | $10.08M USD | -60.8% | -22.0% | 60.3% | |
| LTM Mar 2026 | $8.17M USD | -33.3% | -9.2% | 59.0% | |
| LTM Mar 2026 | $7.36M USD | +42.2% | — | 26.1% | |
| LTM Mar 2026 | $2.64M USD | +336.0% | +112.4% | — | |
| Peer median (excluding CRBU) | — | -10.1% | +4.4% | 59.6% | |
Competitors are the stored peer set for CRBU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (66.92M) | (99.42M) | (102.07M) | (149.11M) | (148.13M) |
| Depreciation & Amortization | 984K | 3.64M | 3.53M | 3.93M | 3.65M |
| Deferred Income Tax | 0 | (95K) | 0 | 0 | (548K) |
| Stock-Based Compensation | 3.45M | 11.72M | 13.75M | 16.71M | 12.68M |
| Change in Working Capital | 29.07M | (4.11M) | (7.32M) | (5.11M) | (484K) |
| Accounts Receivables | (2.96M) | 3.46M | 805K | 608K | 272K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.14M | (2.72M) | 1.82M | (354K) | 3.25M |
| Other Working Capital | 30.89M | (4.85M) | (9.94M) | (5.37M) | (4.01M) |
| Other Non-Cash Items | 904K | 9.02M | (1.18M) | (4.61M) | 21.84M |
| Operating Cash Flow | (32.52M) | (90.97M) | (93.29M) | (138.2M) | (110.99M) |
| Capital Expenditures | (3.12M) | (6.45M) | (11.61M) | (6.51M) | (1.36M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (173.28M) | (339.06M) | (394.76M) | (304.39M) | (150.37M) |
| Sales of Investments | 0 | 252.87M | 338.19M | 397.49M | 252.83M |
| Other Investing Activities | (1M) | (600K) | 0 | (1.61M) | 1.14M |
| Investing Cash Flow | (176.4M) | (93.25M) | (68.18M) | 86.61M | 102.24M |
| Debt Repayment | 1.03M | 0 | 0 | 0 | 0 |
| Common Stock Issued | 321.02M | 2.13M | 152.72M | 15.19M | 4.82M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.55M | 0 | 1.58M | 1.53M | 0 |
| Financing Cash Flow | 433.43M | 2.13M | 154.3M | 16.72M | 4.82M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 224.51M | (182.08M) | (7.18M) | (34.87M) | (3.93M) |
| Free Cash Flow | (35.64M) | (97.42M) | (104.9M) | (144.71M) | (112.35M) |
Caribou Biosciences, Inc.
NASDAQ:CRBU
Intrinsic Alpha fair value
Locked
Current Price
$0.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.